Skip to content
Peptide Laboratory Evidence Review

The sample desk

An unknown sample. Peptide Laboratory Evidence Review

A seized preparation acquired a chemical identity. I like an instrument with a clearly stated job.

Follow the sampleChoose a measurement
A technician checks the front of a mass spectrometer in an analytical laboratory

Chemical identification

A preparation seized in an anti-doping case had an uncertain identity. In a 2010 paper, high-resolution LC-MS/MS identified CJC-1295 in the material. The initials describe an analytical method, liquid chromatography with tandem mass spectrometry. The result was a name for the substance in that sample.

Such a modest analytical success appeals to me. It set out to identify something and did so. The satisfaction is real, even though a chemical identity leaves purity, safety and usefulness as separate questions. A machine can be very convincing within its remit.

The more interesting trouble starts when that confidence travels. An identified peptide becomes a story about recovery; a higher hormone value becomes a story about feeling younger. The measurements in between give me much more to puzzle over. CJC-1295 blood studies, tesamorelin scans and MOTS-c measurements in people receiving dialysis offer quite different answers. That variety is more absorbing than a catalogue of promised effects.

A hormone followed over days

CJC-1295 has an unusually persistent form. An attachment called DAC allows it to bind albumin, a plentiful blood protein. In healthy adults given the long-acting form, average growth hormone rose 2- to 10-fold for 6 days or more, and IGF-1 rose 1.5- to 3-fold for 9–11 days.

Then there is the rhythm. A separate study found that growth-hormone pulses persisted while the level between pulses rose. That raised baseline surprised me. A smooth plateau had seemed more plausible. The CJC-1295 page follows that raised baseline, the different forms and the safety questions that a lasting hormone response creates.

Abdominal measurements

Tesamorelin makes this a story about anatomy. A trial in adults living with HIV and abdominal fat accumulation measured changes in visceral fat and liver fat. Visceral fat is the fat around internal organs, an area a scan can distinguish from the fat beneath the skin.

For me, location makes the result worth examining. The trial can say where fat changed and in whom. Tesamorelin has a specific approved use for excess abdominal fat in HIV-associated lipodystrophy; the findings do not establish general weight loss. The tesamorelin page stays with the scans, their units and the return of visceral fat after treatment stopped.

Dialysis blood

MOTS-c brings a different complication. It is a mitochondrial peptide, studied in energy use and cellular stress. In a cohort of people receiving long-term dialysis, higher circulating MOTS-c was associated with mortality and cardiovascular risk. The participants were observed; nobody was given MOTS-c as an intervention.

That result resists an easy “more is better” story. I have no urge to discard that association merely because MOTS-c improved physical performance in mice. The human blood finding and the mouse treatment finding describe different situations. MOTS-c deserves room for both.

Investigations

The comparison desk puts those questions alongside their measurements. The reading list includes the analytical paper, the human trials and the cell and animal work.